The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Primary Purpose
Bowel Disease, Liver Diseases, Pancreas Disease
Status
Withdrawn
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Ropivacaine-Sufentanil
Dextrose 5
Sponsored by
About this trial
This is an interventional treatment trial for Bowel Disease focused on measuring Major abdominal surgery, epidural, environmental footprint
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing elective reconstructive foot and ankle surgery
- Patients eligible for popliteal and saphenous nerve block
- All adults 18 years of age or older
- Capable to give consent
Exclusion Criteria:
- Patients who are unable to give consent
- Local anaesthetic allergy
- Hemidiaphragm paresis on the contralateral side to the block/surgery site
- Bleeding diathesis
- Coagulopathy
- Pre-existing neurological deficits
- Patients with a Body Mass Index >35
- Patients with significant comorbidities, physiological limitations, and allergies that are unable to tolerate the protocolized induction and maintenance of anesthesia.
Sites / Locations
- University of Alberta Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
PRE-GA
POST-GA
Arm Description
14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
Outcomes
Primary Outcome Measures
Average age-adjusted MAC of sevoflurane
The average age-adjusted end- tidal minimum alveolar concentration (MAC) will be calculated by averaging the end tidal MAC required to maintain the depth of anesthesia as measured by PSI between 25-50 intra-operatively. This will be compared between the two groups.
Secondary Outcome Measures
Intraoperative heart rate
Intraoperative heart rate (in beats/minute) will be documented at 5 minute interval and compared between the two groups
Intraoperative opioid use
Intraoperative use of short acting opioid (in microgram/Kg) as per the study protocol will be recorded and compared between the two groups
Postoperative opioid use in PACU
Total amount of opioids (in mg of morphine equivalents) in the PACU and over the first 24 postoperative hours will be recorded and compared between the two groups
Maximum pain scores in the first 24 post-operative hours
Maximum pain scores will be recorded using numerical rating scale (NRS) of 0-10 (where 0=no pain and 10= maximum pain) on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and compared between the two groups
Nausea and vomiting in the first 24 post-operative hours
Nausea scores (on a Likert scale of 1-4 where 1 = no nausea, 2= mild nausea, 3= moderate nausea and 4= severe nausea) and incidence of vomiting will be recorded on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and will be compared between the two groups
24 hour opioid consumption
Frequency and total consumption of opioids (in morphine equivalents) over the first 24 postoperative hours will be recorded and compared between the two groups
The sedation score in PACU
Sedation scores will be recorded at 15 minute intervals based on Ramsay sedation scale (1-6) and will be compared between the two groups
Temperature testing ("Cold test")
Sensory testing of the abdominal dermatomes will be performed in the PACU at 30 minutes of arrival to PACU to document the success of the block
Intraoperative vasopressor usage
Amount and frequency of the intraoperative usage of vasopressor (phenylephrine in micrograms) will be documented and compared between the two groups
Intraoperative mean blood pressure
Intraoperative mean blood pressure (in mm Hg) will be documented at 5 minute interval and compared between the two groups
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04021264
Brief Title
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Official Title
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Inability to enroll participants.
Study Start Date
August 1, 2019 (Actual)
Primary Completion Date
January 1, 2022 (Actual)
Study Completion Date
January 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Major abdominal surgery - like non-laparoscopic bowel resection, liver, gastric, or pancreas surgery - is performed under general anesthesia. Pain control for after the surgery can be achieved purely with intravenous and oral pain medication or in combination with freezing of the nerves. Nerve freezing (nerve block) placed before surgery has the potential to substantially reduce the amount of inhaled anesthetic given to the patient during surgery. This can benefit the patient with being more awake and crisp more quickly after surgery. It can also reduce cost to the system. A further benefit which has received very little attention so far, is that reducing the amount of inhaled anesthetic given also lowers the environmental footprint created by the anesthetic.
The investigators of the proposed study plan to quantify the amount of inhaled anesthetic used for each case and will compare how the consumption is affected by whether the epidural block is applied before or after surgery. Patients will have a nerve block catheter (epidural catheter) placed prior to the induction of general anesthetic by an experienced regional anesthesiologist. The epidural catheter will be bolused with a solution to which the anesthesiologist is blinded which will either be local anesthetic or dextrose (sham). The general anesthetic will be conducted according to a the protocol with the aim of maintaining a standard anesthetic depth monitored by patient state index (PSI). Measurements of the MAC-Value (minimum alveolar concentration) of inhaled anesthetic will be recorded every five minutes and will be noted down by a blinded observer. At the end of the case the anesthesiologist blinded to the solution will inject another solution (now a dextrose (sham) or local anesthetic before the patient is woken up.
Detailed Description
Following ethics approval, eligible patients meeting the inclusion/exclusion criteria will be consented in pre-assessment unit or day surgery ward at least 2 hours prior to their surgery. Patients will then be randomized into two groups:
Epidural catheter insertion with 14 mL of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil injection (Treatment group) Epidural catheter insertion with 14 mL normal saline injection (Sham group) The patient, anesthesia provider, data recorder, OR staff and Post Anaesthetic Care Unit (PACU) nurses, will be blinded at the beginning of the case. After randomization, each patient will receive a clear 20 mL syringe containing either the Treatment or the Sham solution. Prior to induction of general anesthesia, an epidural catheter will be inserted by an experienced acute pain physician who has been performing epidural blocks for at least 5 years. Catheter placement will be verified by a single test dose of 60 mg lidocaine to exclude subarachnoid tip location.
Induction of general anesthesia will follow a standardized protocol with the intravenous administration of fentanyl (2 mcg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg). General anesthesia will initially be maintained with sevoflurane at 1.0 age-adjusted Minimal Alveolar Concentration (MAC). Subsequently, the age-adjusted MAC will be titrated to achieve an intraoperative PSI target of 25-50 (Sedline, Masimo®), and intraoperative heart rate (HR) and mean blood pressure (MBP) target of +/-30% baseline values. The anaesthesiologist will have the ability to administer IV boluses of analgesic (remifentanil 0.5mcg/kg) at if the PSI is <50 and the MBP or HR is above 30% of baseline. Vasopressors such as phenylephrine (100 mcg IV bolus) and ephedrine (5 mg IV bolus) can be used as last-line therapy to treat hypotension that is unresponsive to MAC adjustments. The age-adjusted MAC value will be recorded every 5 minutes starting at the time of skin incision until the time of skin closure. In addition, intraoperative analgesic and vasopressor usage are recorded. The epidural catheter will be run continuously throughout the surgery with 4-6 ml/h with study drug number 1 as per randomization - so either treatment or sham. After the conclusion of MAC recording and prior to emergence from general anesthesia, the anaesthesiologist will be unblinded to the randomized groups, and the patients who received Sham solution will be given 20 mL of the treatment solution via the interscalene catheter to ensure patients receive adequate analgesia postoperatively.
Postoperatively, patients will be transported to PACU where the distribution of the sensory or motor block will then be checked and recorded 30 minutes after arriving in PACU in both groups. The NRS for pain will also be recorded in PACU at 0, 15, 30 and 45 minutes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bowel Disease, Liver Diseases, Pancreas Disease, Anesthesia; Functional
Keywords
Major abdominal surgery, epidural, environmental footprint
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Model Description
Double-blinded, randomized controlled, prospective
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PRE-GA
Arm Type
Active Comparator
Arm Description
14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
Arm Title
POST-GA
Arm Type
Sham Comparator
Arm Description
14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
Intervention Type
Drug
Intervention Name(s)
Ropivacaine-Sufentanil
Intervention Description
Local anesthetic injection
Intervention Type
Drug
Intervention Name(s)
Dextrose 5
Intervention Description
Sham injection
Primary Outcome Measure Information:
Title
Average age-adjusted MAC of sevoflurane
Description
The average age-adjusted end- tidal minimum alveolar concentration (MAC) will be calculated by averaging the end tidal MAC required to maintain the depth of anesthesia as measured by PSI between 25-50 intra-operatively. This will be compared between the two groups.
Time Frame
Intraoperative measurement done at the end of anesthetic
Secondary Outcome Measure Information:
Title
Intraoperative heart rate
Description
Intraoperative heart rate (in beats/minute) will be documented at 5 minute interval and compared between the two groups
Time Frame
Intraoperative measurement
Title
Intraoperative opioid use
Description
Intraoperative use of short acting opioid (in microgram/Kg) as per the study protocol will be recorded and compared between the two groups
Time Frame
Intraoperative measurement
Title
Postoperative opioid use in PACU
Description
Total amount of opioids (in mg of morphine equivalents) in the PACU and over the first 24 postoperative hours will be recorded and compared between the two groups
Time Frame
Up to 24 postoperative hours
Title
Maximum pain scores in the first 24 post-operative hours
Description
Maximum pain scores will be recorded using numerical rating scale (NRS) of 0-10 (where 0=no pain and 10= maximum pain) on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and compared between the two groups
Time Frame
Up to 24 postoperative hours
Title
Nausea and vomiting in the first 24 post-operative hours
Description
Nausea scores (on a Likert scale of 1-4 where 1 = no nausea, 2= mild nausea, 3= moderate nausea and 4= severe nausea) and incidence of vomiting will be recorded on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and will be compared between the two groups
Time Frame
Up to 24 postoperative hours
Title
24 hour opioid consumption
Description
Frequency and total consumption of opioids (in morphine equivalents) over the first 24 postoperative hours will be recorded and compared between the two groups
Time Frame
Up to 24 postoperative hours
Title
The sedation score in PACU
Description
Sedation scores will be recorded at 15 minute intervals based on Ramsay sedation scale (1-6) and will be compared between the two groups
Time Frame
1st postoperative hour
Title
Temperature testing ("Cold test")
Description
Sensory testing of the abdominal dermatomes will be performed in the PACU at 30 minutes of arrival to PACU to document the success of the block
Time Frame
1st postoperative hour
Title
Intraoperative vasopressor usage
Description
Amount and frequency of the intraoperative usage of vasopressor (phenylephrine in micrograms) will be documented and compared between the two groups
Time Frame
Intraoperative period
Title
Intraoperative mean blood pressure
Description
Intraoperative mean blood pressure (in mm Hg) will be documented at 5 minute interval and compared between the two groups
Time Frame
Intraoperative period
10. Eligibility
Sex
All
Gender Based
Yes
Gender Eligibility Description
All gender identification and self-representation is eligible
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients undergoing elective reconstructive foot and ankle surgery
Patients eligible for popliteal and saphenous nerve block
All adults 18 years of age or older
Capable to give consent
Exclusion Criteria:
Patients who are unable to give consent
Local anaesthetic allergy
Hemidiaphragm paresis on the contralateral side to the block/surgery site
Bleeding diathesis
Coagulopathy
Pre-existing neurological deficits
Patients with a Body Mass Index >35
Patients with significant comorbidities, physiological limitations, and allergies that are unable to tolerate the protocolized induction and maintenance of anesthesia.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vivian HY Ip, MD
Organizational Affiliation
University of Alberta
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Lora Pencheva, MD
Organizational Affiliation
University of Alberta
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Rakesh V Sondekoppam, MD
Organizational Affiliation
University of Alberta
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Timur JP Özelsel, MD, DESA
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2G3
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
We'll reach out to this number within 24 hrs